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Purpose. To optimize a rabbit dry eye model induced by topical instillation of benzalkonium chloride (BAC), reduce the days of
instillation of the original model by increasing the concentration of BAC from 0.1% to 0.2%. Materials and Methods. An ex-
perimental, prospective, and randomized study was performed on 10 male New Zealand white rabbits, divided into two groups,
considering both eyes: 5 rabbits as control (n� 10) and 5 rabbits with 0.2% BAC treatment (n� 10). Saline solution (control) and
0.2% BAC were instilled for 5 consecutive days, twice daily. Tear secretion with and without anesthesia, tear breakup time, tear
osmolarity, corneal staining, conjunctival hyperemia, density of goblet cells, height of mucin cloud, and transcript levels of IL-6
were measured before and after the treatment. Results. After the instillation of 0.2% BAC for 5 consecutive days, there was a
significant increase in tear secretion without anesthesia (P< 0.001), corneal staining (P< 0.001), conjunctival hyperemia
(P< 0.001), and levels of IL-6 mRNA (P � 0.005) compared to the control group. Conversely, there was a decrease in tear
secretion with anesthesia (P< 0.001), tear breakup time (P � 0.007), tear osmolarity (P< 0.001), density of goblet cells
(P< 0.001), and height of mucin cloud (P< 0.001). Conclusions. )e topical instillation of 0.2% BAC for 5 consecutive days, twice
daily, was a proper procedure to induce a rabbit dry eye model, reducing the number of days of instillation compared to the
original model (14 days).
1. Introduction
In 2017, the TFOS DEWS II defined the dry eye as “a
multifactorial disease of the ocular surface characterized by a
loss of homeostasis of the tear film, and accompanied by
ocular symptoms, in which tear film instability and hyper-
osmolarity, ocular surface inflammation and damage, and
neurosensory abnormalities play etiological roles” [1]. Dry eye
affects the quality of life of a large part of the world pop-
ulation [2], between 5% and 50%, depending on geographic
location and methodology used to diagnose the disease [3].
)e discovery of new diagnostic biomarkers and treat-
ments for dry eye requires the use of animal models. Based
on the etiology and classification of dry eye, different animal
models have been developed over the years [4, 5]. In rabbits,
dry eye has been induced by many procedures such as
dacryoadenectomy [6], female and male castration [7, 8],
desiccating stress [9], induced autoimmune dacryoadenitis
[10], injection of the lacrimal gland with concanavalin A
[11], injury of the drainage duct [12], nerve denervation [13],
and topical instillation of atropine [14] or benzalkonium
chloride (BAC) [15]. )e current publication is focused on
the topical instillation of BAC.
BAC is a preservative agent, which is incorporated into
the formulation of eye drops and contact lens solutions. It is
frequently used in glaucoma medication. BAC could pro-
duce undesirable side effects over the ocular surface of these
patients because of its toxicity and irritancy [16, 17]. )e
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concentrations of BAC used in commercial formulations are
between 0.005% and 0.02%, which lyse the membranes of
corneal epithelium cells [18]. BAC also produces damage in
the structure of tear film constituents [19], corneal inner-
vation [20], and conjunctival cells [21]. )us, the topical
instillation of BAC has been used to develop dry eye models
in rabbits [15] and mice [22].
Animal models based on the topical administration of
BAC allow the evaluation of different dry eye markers re-
lated to tear quality, ocular surface damage, and inflam-
mation. In rabbits, several studies used this model to
evaluate the efficacy of different eye drops containing
hyaluronic acid [23, 24], povidone [23], epigallocatechin
gallate [24, 25], virally inactivated serum [26], carbox-
ymethyl pullulan [27], or cyclosporine A [28]. )is model
was also used to evaluate new treatments using drug delivery
systems such as nanoparticles modified with anti-inflam-
matories [29] or epigallocatechin gallate/hyaluronic acid
[30] and cyclosporine A-eluting contact lenses [31]. Other
authors studied the efficacy of the intracanalicular injection
of a chitosan-based hydrogel for dry eye treatment [32] and
the influence of dry eye in the glaucoma filtration surgery
[33].
)e original rabbit dry eye model induced by topical
instillation of BAC was developed by Xiong et al. [15] who
proposed the instillation of 0.1% BAC for 2 consecutive
weeks, twice daily. Additionally, they evaluated higher
concentrations of BAC (0.2%, 0.3%, 0.5%, and 1%) which
were not safe, but they did not report results about this fact.
Other authors used this model induced through the instil-
lation of 0.1% BAC for three [33] and four [24, 26, 30]
consecutive weeks. In mice, the original dry eye model was
developed by Lin et al. [22] who instilled 0.2% BAC for 1
week, twice daily, reducing the time by half, compared to the
same model in rabbits. )is mouse dry eye model has been
used effectively by other authors [34, 35].
)e current study is focused on the idea of reducing the
time of instillation of BAC necessary to induce the rabbit dry
eye model by increasing the concentration of BAC from
0.1% to 0.2%.
Based on the previous studies, the purpose of the current
study was to optimize the original rabbit dry eye model
induced by topical instillation of BAC [15], reducing the
number of days of instillation. To that end, 0.2% BAC was
instilled for 5 consecutive days, twice daily (except the last
day). Signs of dry eye related to tear quality, ocular surface
damage, and inflammation were evaluated.
2. Materials and Methods
2.1. Design of the Study. An experimental, prospective, and
randomized study was performed in compliance with the
ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research and with the Directive 2010/63/EU of the
European Parliament and of the Council on the protection of
animals used for scientific purposes.
All the trials were performed before (pre) and after (post)
the instillation of saline solution (Avizor, Madrid, Spain) as
control and 0.2% BAC (Merck, Darmstadt, Germany). Two
instillations of 35 μl per day for 5 consecutive days were
performed: one in the morning (10 a.m.) and another in the
evening (6 p.m.), from Monday to Friday. On the last day,
only one instillation during the morning was done and the
measurements were taken after 1 hour. In total, nine in-
stillations per rabbit were performed. )e concentration of
BAC and the number of days of instillation were selected
based on the results of a previous pilot study. )e order of
the trials was as follows: tear osmolarity, tear secretion
without anesthesia, slit-lamp examination, conjunctival
cytology, and tear secretion with topical anesthesia. Topical
anesthesia to assess tear secretion was instilled once the rest
of the measurements were done.
2.2. Animals. Ten male New Zealand white rabbits were
used in the study, considering both eyes (n eyes� 20),
randomly divided into two groups: 5 rabbits as control
(n� 10) and 5 rabbits with 0.2% BAC (n� 10). )e weight of
the rabbits was between 2.0 and 2.5 kg. )e rabbits were kept
in cages with free access to food and water. )e rabbits were
kept under controlled 12 h light-dark cycles, a temperature
of 18°C, and a humidity of 30%. Before experimentation, the
rabbits were kept in the cages for 7 days to get them used to
their new housing conditions.
2.3. Pilot Study. A pilot study was performed to establish the
final concentration of BAC (0.2%) and the number of days of
instillation (5 days). )e presence of undesirable signs such
as corneal ulcer, neovascularization, and scarring was
evaluated over time with the slit-lamp VX75 (Luneau
Technology, Chartres, France). Eight rabbits were used: 2
rabbits received saline solution, 2 rabbits received 0.1% BAC,
2 rabbits received 0.2% BAC, and 2 rabbits received 0.3%
BAC. All the treatments were instilled for 2 consecutive
weeks, twice daily, doing two washout periods during the
weekends.
Table 1 specifies the presence of corneal ulcer, neo-
vascularization, and scarring over time with the different
concentrations of BAC, while Figure 1 shows a represen-
tative image of the corneal ulcer and scarring produced in
the rabbits.
2.4. Tear Secretion, Breakup Time, and Osmolarity. Tear
secretion was measured using Schirmer’s strip (Lenticon,
Madrid, Spain) for 5min. Eachmillimeter of the strip soaked
with tear corresponds to 1 μl. )e paper strip was positioned
in the inferior temporal eyelid, and the rabbits’ eyes were
closed during the measurements to avoid reflex blinking.
)e measurements were taken with and without topical
anesthesia. For measurements with anesthesia, two drops of
a commercial eye drop containing 5mg/ml tetracaine hy-
drochloride and 0.5mg/ml naphazoline hydrochloride
(Alcon Cus´ı, Barcelona, Spain) were instilled with a dif-
ference of 5min between instillations. )e measurements
were taken 5min after the last instillation.
Tear breakup time was measured during the slit-lamp
examination. For its evaluation, 5 μL of commercial 2%
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fluorescein sodium (Alcon Cusi, Barcelona, Spain) was in-
stilled over the ocular surface.)emeasurements were taken
with a timer after manually force two consecutive blinks to
the rabbits.
Tear osmolarity was measured with the medical device
TearLab (TearLab Corporation, San Diego, California,
United States), an osmometer which analyses the electrical
impedance of 50 nL of the tear film. All the measurements
were taken in the same room at 18°C. Both eyes were
measured consecutively, first the right eye and then the left
one.
2.5. Slit-Lamp Examination. )e signs of ocular surface
damage were evaluated with the slit-lamp VX75 by using the
same commercial 2% fluorescein sodium as for measuring
tear breakup time. )e Efron Grading Scales were used to
quantify the severity of corneal staining and conjunctival
hyperemia, grading the signs as normal (0), trace (1), mild
(2), moderate (3), and severe (4) [36].
Additionally, corneal ulcer, neovascularization, and
scarring were assessed to confirm the safety of the instillation
of 0.2% BAC.
2.6. Conjunctival Cytology. Conjunctival cytology was done
to collect the superficial conjunctival cells with the medical
device EYEPRIM (Opia Technologies, Paris, France). Cy-
tology of the superior and inferior quadrants of the bulbar
conjunctiva of each eye was taken.
Superior cytology was fixed in 96% ethanol for 24 hours
at 4°C.)en, the samples were stained with the hematoxylin-
periodic acid Schiff (PAS) procedure. )e goblet cells of the
conjunctiva were evaluated by using the confocal micros-
copy Axiovert 200M (Zeiss, Oberkochen, Germany). )e
density of goblet cells (Figure 2) was quantified in 5 different
regions of each sample.)e height of mucin cloud, including
the cell thickness, was quantified in 15 different cells of each
sample. Both sample visualization and their measurements
were done by using the LSM Image Browser software (Zeiss).
Table 1: Results of the pilot study on the presence of corneal ulcer, neovascularization, and scarring after the instillation of saline solution
(control) and the different concentrations of BAC (0.1%, 0.2%, and 0.3%).
Corneal sign Group
Number of instillations
First week Second week
5 10 15 20
Ulcer
Control − − − −
0.1% BAC − − − −
0.2% BAC − − + +
0.3% BAC − + + +
Neovascularization
Control − − − −
0.1% BAC − − − −
0.2% BAC − − + +
0.3% BAC − + + +
Scarring
Control − − − −
0.1% BAC − − − −
0.2% BAC − − + +
0.3% BAC − + + +
)e positive and negative signs indicate the presence or absence of these signs, respectively.
Corneal ulcer
and scarring
Figure 1: Representative image of corneal ulcer and scarring produced by the topical instillation of 0.3% BAC after 10 instillations. )ese
signs were similar after the instillation of 0.2% BAC, but they appeared later (after 15 instillations).)e lack of transparency of the cornea can
be observed, due to a stromal ulcer by using the technique of indirect illumination with a slit lamp.
Journal of Ophthalmology 3
)e hematoxylin of the samples was excited by a wavelength
of 488 nm, and its signal was filtered for a range between 505
and 530 nm. On the other hand, the PAS was excited by a
wavelength of 543 nm, and its signal was filtered for 560 nm.
)e Z-stack to visualize the three-dimensional cells was done
for a pupil size of 180 μm and a stack interval of 0.25 μm. All
these procedures were done according to Peral and Pintor
[37].
Inferior cytology was fixed in RNAlater ()ermo Fisher
Scientific, Waltham, Massachusetts, USA) for 24 hours at
4°C. )en, RNAlater was removed, and the samples were
stored at −80°C for their posterior processing.
2.7. RNA Isolation, cDNA Synthesis, and Quantitative PCR.
)e purpose of the following procedures was to quantify the
levels of interleukin 6 (IL-6) mRNA in conjunctival cells.
Total RNA was isolated from inferior cytology with the
QIAshredder and RNeasy Mini Kit (Qiagen, Madrid, Spain)
following the manufacturer’s instructions.
First-strand cDNA synthesis was performed from 22 μL
of total RNA, using High Capacity cDNA Reverse Tran-
scription Kit and random hexamer primers ()ermo Fisher
Scientific). Quantitative PCR (qPCR) was performed in
triplicate using cDNA, the QuantiTect SYBR Green Kit
(Qiagen), and IL-6 specific primers (5′-GCCTCA-
CAAACTTCCTGGAG-3′/5′-GATGGTGTGTTCT-
GACCGTG-3′) on a QuantStudio 3 system ()ermo Fisher
Scientific). )e thermal cycler program was 15min at 95°C,
followed by 40 cycles of 15 s at 94°C, 30 s at 55°C, and 34 s at
72°C (data collection step). Nontemplate and nonreverse
transcribed controls were included in all the experiments.
Analysis of the melting curves confirmed the specificity
of PCR and the absence of primer-dimers. )e hypoxan-
thine-guanine phosphoribosyltransferase 1 (HPRT1) gene
(5′-CTGGCAAAACAATGCAGACCT-3′/5′-GTCCTTTTCAC-
CAGCAGGCTT-3′) was used as an internal control to
normalize mRNA relative expression, after its validation for
qPCR. Validation of the internal control gene and qPCR data
analysis were performed by the 2−ΔCt and 2−Δ∆Ct method,
respectively, once confirmed that the amplification efficiency
of IL-6/HPRT1 primer pairs was similar and close to a value
of 2.
2.8. Statistical Analysis. Statistical analysis was performed
using the SPSS Statistics 23 software (IBM, Chicago, Illinois,
United States). )e normality of each distribution was
assessed using the Shapiro–Wilk test. )e statistical com-
parison between the baseline measurements (PRE) and after
the instillation of the treatments (POST) was done using
Student’s t-test for paired samples, in case of normal dis-
tributions, and the Wilcoxon signed-rank test, in case of
nonnormal distributions. Additionally, the statistical com-
parison between the effect of each treatment was done using
Student’s t-test for independent samples, in case of normal
distributions, and the Mann–Whitney U test, in case of
nonnormal distributions. A statistical significance of 95%
was established (P � 0.05) in all the tests.
)e studied parameters were tear secretion without
anesthesia, tear secretion with anesthesia, tear breakup time,
tear osmolarity, corneal staining, conjunctival hyperemia,
density of goblet cells, height of mucin cloud, and levels of
IL-6 mRNA. Results are shown as mean± SD.
3. Results
)e instillation of 0.2% BAC for 5 consecutive days did not
produce corneal ulcer, neovascularization, or scarring in any
rabbit, confirming the safety of this procedure. Figure 2
shows the ocular surface damage produced by the instillation
Control (before) Control (aer) 0.2% BAC (before) 0.2% BAC (aer)
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Figure 2: Representative images of ocular surface damage in terms of corneal staining and density of goblet cells before and after the
instillation of saline solution (control) and 0.2% benzalkonium chloride (BAC) for 5 days. After the instillation of 0.2% BAC, an increase is
observed in corneal superficial punctate and a decrease in the density of goblet cells (brightest cells).
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of 0.2% BAC in terms of corneal staining and density of
goblet cells.
Table 2 summarizes the values of all the parameters
under study before and after the instillation of 0.2% BAC
and saline solution (control) for 5 consecutive days.
3.1. Tear Secretion, Breakup Time, and Osmolarity. To begin
with the comparison between both groups, Figure 3 shows the
normalized effect of both treatments on tear parameters (tear
secretion, tear breakup time, and tear osmolarity). Con-
cerning tear secretion, different results were found with and
without topical anesthesia. Without anesthesia, it was found a
statistical increase of 85.42± 22.51% after the instillation of
0.2% BAC compared to the control group that suffered a
decrease of 29.41± 14.43% (P< 0.001; comparison between
groups). Conversely, with anesthesia, there was a decrease of
30.30± 5.33% with 0.2% BAC compared to the control group
that showed no statistical differences (P< 0.001).
About tear breakup time, both treatments showed a
statistical decrease, but it was higher after the instillation of
0.2% BAC (70.47± 18.86%) compared to the control group
(22.47± 8.01%) (P � 0.007). Finally, there was a statistical
decrease in tear osmolarity of 5.40± 0.21% after the instillation
of 0.2% BAC compared to the control group (P< 0.001),
which showed a statistical increase of 7.46± 0.30%.
3.2. Slit-Lamp Examination. Figure 4 shows the effect of
both treatments on corneal staining and conjunctival hy-
peremia. )ese values were not normalized in percentage
since they are discrete variables. After the instillation of 0.2%
BAC, there was a deterioration in the score of both corneal
staining (2.60± 0.70) and conjunctival hyperemia
(3.10± 0.74) compared to the control group (P< 0.001),
where there were no statistical differences.
3.3. Conjunctival Cytology. Figure 5 shows the normalized
effect of both treatments on the parameters related to goblet
cells (density of goblet cells and height of mucin cloud). )e
instillation of 0.2% BAC produced a decrease of both the
density of goblet cells (64.32± 19.92%) and height of mucin
cloud (43.15± 1.72%) compared to the control group
(P< 0.001) that showed no statistical differences.
3.4. Quantitative PCR. Figure 6 shows the effect of both
treatments on levels of IL-6 mRNA. )e results were nor-
malized against HPRT1 signal (internal control) and against
levels of IL-6 mRNA in baseline conditions (PRE). In levels
of IL-6 mRNA (fold change), there were no statistical
changes in the control group and was an increase of
44.87± 42.70 with 0.2% BAC (P � 0.005). Comparing the
effect of both treatments, the instillation of 0.2% BAC
produced a 24.52-fold increase.
4. Discussion
)e current study reports on the possibility of reducing the
time necessary to induce a rabbit dry eye model based on the
topical instillation of BAC. It was possible to reduce this time
from 14 days of the original model of Xiong et al. [15] to 5
days of the current one by increasing the concentration of
BAC from 0.1% to 0.2%. )e instillation of 0.2% BAC for 5
consecutive days, twice daily, deteriorated some signs of dry
eye such as tear breakup time, fluorescein corneal staining,
conjunctival hyperemia, density of goblet cells, height of
mucin cloud, and levels of IL-6 mRNA. Conversely, this
instillation increased tear secretion and decreased tear film
osmolarity, which could be associated to the different factors
discussed below.
In terms of safety, the instillation of 0.2% BAC for 5
consecutive days did not produce corneal ulcer or neo-
vascularization. In our previous pilot study, it was observed
that the instillation of 0.2% BAC produced corneal ulcer
during the second week (see Table 1), accompanied by
neovascularization and scarring. Xiong et al. [15] evaluated
higher concentrations of BAC than 0.1% (0.2%, 0.3%, 0.5%,
and 1%), different frequencies of instillation (1–4 times
daily), and different lengths of treatment (1–4 weeks) to
optimize their model. )ey established that higher con-
centrations of BAC than 0.1% caused corneal ulcer, neo-
vascularization, and scarring over a period of 2 weeks.
However, they did not report data about this fact, even
during the first week of evaluation. Since our results did not
show any undesirable effect over the ocular surface, the
instillation of 0.2% BAC for 5 consecutive days could be
considered a proper method to induce dry eye in rabbits. In
agreement with our results, other authors instilled 0.2% BAC
for 1 week to induce dry eye in mice [22, 34, 35]. It should be
taken into consideration that the anatomy and physiology of
rabbits and mice are not the same, but the cornea of mice is
even thinner than the cornea of rabbits [38, 39].
From the safety perspective of this dry eye model, its
success rate could be considered as 100% since none of the
rabbits’ eyes showed undesirable side effects after the in-
stillation of 0.2% BAC for 5 consecutive days. Concerning its
efficacy, 100% of the eyes suffered a deterioration of tear
secretion with anesthesia, tear breakup time, corneal
staining, conjunctival hyperemia, density of goblet cells, and
height of mucin cloud, while 80% of these eyes increased
their levels of IL-6 mRNA.
Concerning tear secretion, it should be noted that the
effect of the instillation of 0.2% BAC was completely dif-
ferent with or without topical anesthesia. Without anes-
thesia, the 0.2% BAC produced an increase in tear secretion
around 36% compared to the control group (see Figure 3(a)),
the opposite effect that would be expected in an aqueous
deficient dry eye [1].)is hypersecretion was associated with
ocular irritation after the instillation of this compound
[16, 17], which could be producing reflex lacrimation.
Conversely, with anesthesia, there was a decrease of tear
secretion as expected, around 34% compared to the control
group (see Figure 3(b)). Our results with anesthesia would
agree with different studies that found a similar decrease in
tear secretion by using both topical [15] and general anes-
thesia [24, 26, 27, 30–33]. )erefore, the use of anesthesia
would be necessary to evaluate tear secretion in this dry eye
model. )e values of tear secretion with anesthesia obtained
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by these mentioned dry eye models were between 3 and
10 μL, performing Schirmer’s test for 5min
[15, 24, 26, 27, 30, 31, 33].
As expected, tear breakup time was reduced after the
instillation of 0.2% BAC around 48% compared to the
control group (see Figure 3(c)). )is severe instability of the
tear film is part of the pathophysiology of dry eye, which
comes from inflammation and damage of the ocular surface
(see Figures 4–6) [40]. In our knowledge, only Choi et al.
[31] evaluated tear breakup time using this model after the
instillation of 0.1% BAC for 2 weeks. )ey found a reduction
of around 73% compared to their control group. Directly
comparing values of tear breakup time with other studies
should be done carefully since these values depend on
different factors such as both volume and concentration of
instilled fluorescein [41].
Tear osmolarity was the other parameter whose results
were not as expected in a dry eye model [1]. In the current
study, the instillation of 0.2% BAC produced a decrease in
tear osmolarity around 13% compared to the control group
(see Figure 3(d)). No studies evaluating tear osmolarity in
this dry eyemodel were found in the scientific literature.)is
decrease in tear osmolarity could be related to the increase in
tear secretion without anesthesia, since osmolarity was also
measured without it. An increase in the tear volume could
dilute the ionic compounds present in tear, reducing its
osmolarity. )is theory is based on the negative correlation
found between tear osmolarity and tear secretion
(r � −0.791, P< 0.001) in the sample of this study. Addi-
tionally, Kim et al. [42] found a negative correlation between
both parameters (r � −0.625, P< 0.001) in primary
Sjo¨gren’s syndrome patients.
In the control group, it was observed that all the tear
parameters, except tear secretion with anesthesia, were
deteriorated after the instillation of saline solution for 5 days
(see Table 2). Since saline solution should not produce any
undesirable effects on the ocular surface, these changes
would be associated with environmental factors.
In relation to ocular surface damage, all the rabbits
reached the maximum score of corneal staining after the
instillation of 0.2% BAC (see Table 2). )is corneal damage
was accompanied by conjunctival damage in terms of
conjunctival hyperemia (see Figure 4(b)) and a reduction in
density of goblet cells around 57% compared to the control
group (see Figure 5(a)). Additionally, the functionality of
these goblet cells was affected considering the reduction in
their height of mucin cloud, around 40% compared to the
control group (see Figure 5(b)). )e severity of these
markers suggests that the instillation of 0.2% BAC is a fast
method to induce ocular surface damage. In the original
rabbit dry eye model, Xiong et al. [15] found a lower corneal
staining score after the instillation of 0.1% BAC for 2 weeks
compared to the current study, but a higher loss of goblet
cells. As expected, other authors found similar ocular surface
damage [23–33]. Additionally, some of them reported a
reduction in epithelial corneal thickness [24, 29, 30], which is
another marker that could be evaluated in this animal model.
On the other hand, the high levels of IL-6 mRNA in
conjunctival cells after the instillation of 0.2% BAC con-
firmed the presence of ocular surface inflammation (see
Figure 6). It should be noted that the standard deviation in
the 0.2% BAC treated group was similar to its mean vari-
ation. )is was because two eyes showed lower levels of IL-6
mRNA than their baseline measurements. )e rest of eyes
showed a range of expression levels from 9.69 to 99.80 times
higher than their baseline measurements. After the instil-
lation of 0.1% BAC, some studies also found an increase in
expression levels of IL-6 [24, 30, 31] and other molecular
biomarkers in conjunctival cells such as IL-1β [30, 31, 33],
IL-8 [24, 30], and TNF-α [24, 30, 31]. Other authors reported
Table 2: Values of all the parameters under study before (pre) and after (post) the instillation of saline solution (control) and 0.2%
benzalkonium chloride (BAC) for 5 days.
Parameter Group
Mean± SD
P value
Pre Post
Tear secretion without anesthesia (μL) Control 11.90± 2.89 8.40± 4.12 0.032∗0.2% BAC 9.60± 3.13 17.80± 4.69 0.008∗
Tear secretion with anesthesia (μL) Control 5.80± 1.03 6.00± 1.15 0.4140.2% BAC 6.60± 0.52 4.60± 0.84 0.004∗∗
Tear breakup time (s) Control 5.03± 1.82 3.90± 1.39 0.036∗∗0.2% BAC 4.30± 1.15 1.27± 0.34 0.005∗∗
Tear osmolarity (mOsm/L) Control 309.70± 13.66 332.80± 13.49 0.008∗0.2% BAC 313.00± 12.75 296.10± 11.71 0.014∗
Corneal staining (score) Control 1.40± 0.70 1.70± 0.95 0.4050.2% BAC 1.40± 0.70 4.00± 0.00 0.004∗∗
Conjunctival hyperemia (score) Control 0.10± 0.32 0.10± 0.32 1.0000.2% BAC 0.30± 0.68 3.40± 0.52 0.004∗∗
Density of goblet cells (cells/mm2) Control 683.57± 77.63 636.19± 140.20 0.3040.2% BAC 703.12± 75.76 250.89± 77.71 <0.001∗
Height of mucin cloud (μm) Control 27.48± 0.74 26.71± 0.79 0.4690.2% BAC 27.72± 0.54 15.76± 0.63 <0.001∗
Expression levels of IL-6 (fold change) Control 0.020± 0.031 0.017± 0.008 0.7700.2% BAC 0.032± 0.063 0.322± 0.252 0.002∗∗
Statistical comparison was done between pre and postvalues. ∗P< 0.05, Student’s t-test for paired samples. ∗∗P< 0.05, the Wilcoxon signed-rank test.
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a decrease in functionality of goblet cells in terms of ex-
pression levels of MUC5AC [15, 29].
)is rabbit dry eye model has been used to measure the
efficacy of different eye drops and drug delivery systems for
dry eye treatment [23–32]. Some studies applied their
treatments while the BAC was being instilled [23, 27–29, 31]
and other studies after the instillation of BAC, during the
period of reversibility of the dry eye model [24–26, 30, 32]. Li
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Figure 4: Variation of corneal staining (a) and conjunctival hyperemia (b) after the instillation of saline solution (control) and 0.2%
benzalkonium chloride (BAC) for 5 days. )e instillation of 0.2% BAC produced a deterioration of both variables compared to the control
group. Positive values represent a deterioration compared to their baseline. Statistical comparison wasmade between both groups. ∗P< 0.05,
the Mann–Whitney U test.
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Figure 3: Normalized effect on tear parameters after the instillation of saline solution (control) and 0.2% benzalkonium chloride (BAC) for
5 days. Tear secretion without (a) and with anesthesia (b), tear breakup time (c), and tear osmolarity (d). )e instillation of 0.2% BAC
decreased tear secretion with anesthesia, tear breakup time, and tear osmolarity compared to the control group, while tear secretion without
anesthesia was increased. Values higher and lower than 100% represent an increase or decrease, respectively, compared to their baseline.
Statistical comparison was done between both groups. ∗P< 0.05, Student’s t-test for independent samples. ∗∗P< 0.05, theMann–WhitneyU
test.
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et al. [43] studied the stability of the original model of Xiong
et al. [15], establishing that the signs of dry eye were sus-
tained between 2 and 3 weeks after the last instillation of
0.1% BAC. Taking into consideration that both alternatives
were effective, it would be logical to apply the treatments
while the BAC is being instilled, in order to save time in the
experiments. However, a comparison between both alter-
natives should be considered for future studies, considering
that if the dry eye is induced in a shorter time, the recovery of
clinical signs could be different compared to the study of Li
et al. [43].
)e current study had some limitations that could be
improved in future studies. Considering that tear osmolarity
was decreased after the instillation of 0.2% and its negative
correlation with tear secretion without anesthesia, topical
anesthesia could be probably necessary to measure tear
osmolarity in this dry eye model. Besides, the number of
days of instillation could have been reduced even more if the
rabbits had been evaluated every day during the pilot study.
5. Conclusions
In conclusion, the topical instillation of 0.2% BAC for 5
consecutive days, twice daily, was a proper procedure to
induce a rabbit dry eye model, reducing the number of days
of instillation compared to the original model (14 days) [15].
Additionally, it is emphasized that topical or general an-
esthesia must be used in future studies to evaluate tear
secretion.
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